A good understanding of the market is fundamental in making an educated “Go – No Go” decision. If you decide to “Go,” then knowing how to approach the market is critical in selling a pharmaceutical product successfully. Producing accurate market analyses in emerging markets is challenging; exceptional expertise and understanding are required to turn sometime suspect quality, often-times ambiguous data into reliable and actionable information.

Historically, pharmaceutical market data in emerging markets has been sparse. In working with a client, we ideally would like to provide consistently high-quality data across a variety of therapeutic areas, but such data may not exist! As a result, we access a variety of sources. We regularly use databases of private providers, various government agencies, trade associations, and medical publications, as well as consult with experts and government officials. We compare, contrast and crosscheck these in order to ensure that we have the most accurate and reliable information available.

We analyze the data to distill individual strategies. We review the historical market for a particular need, identify key drivers, and try to forecast future dynamics in the relevant environment. We appraise competitive forces (if they exist in the environment, e.g., introduction of new competing products, appearance of substitutes, manufacturers’ market-related decisions), and regulatory influences. Based on this information, we estimate potential product sales, and issue recommendations on product marketing (e.g., pricing policy).

We ensure superior quality research because we utilize our expansive network of contacts to access key experts and decision-makers in the field, and because we employ professionals of the highest caliber. Any Raifarm employee engaged in market research has had years of experience, having previously worked in senior positions in marketing at local offices of leading pharmaceutical companies.

“Such a superior job. User-friendly...vertical and horizontal logic...high quality in-depth analysis”
General Manager, top-10 global pharma company